BHC
Bausch Health Companies Inc.
BHC lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to hold roughly steady.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Weak |
BHC's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BHC PE Valuation
BHC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect BHC's earnings, revenue and profitability to hold roughly steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.30 | — |
| Q3 2026 | -$2.29 | -339% |
| Q2 2026 | -$2.96 | -1284% |
| Q1 2026 | -$3.24 | -$3.12 |
| Q4 2025 | $0.42 | +$0.55 |
| Q3 2025 | $0.96 | +$1.44 |
| Q2 2025 | $0.25 | +$1.53 |
| Q1 2025 | -$0.12 | +$1.12 |
| Q4 2024 | -$0.13 | +$1.49 |
BHC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +9.7% |
| Q2 2026 | $2.9B | +13% |
| Q1 2026 | $2.5B | +12% |
| Q4 2025 | $2.8B | +9.3% |
| Q3 2025 | $2.7B | +6.8% |
| Q2 2025 | $2.5B | +5.3% |
| Q1 2025 | $2.3B | +4.9% |
| Q4 2024 | $2.6B | +6.3% |
BHC's revenue has grown year over year for 15 quarters in a row: $2.9B last quarter, up 9.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +10 points |
| Q2 2026 | 26% | +8.4 points |
| Q1 2026 | -38% | -50 points |
| Q4 2025 | 17% | -4.9 points |
| Q3 2025 | 23% | +10 points |
| Q2 2025 | 18% | +1.4 points |
| Q1 2025 | 12% | -0.8 points |
| Q4 2024 | 22% | +6.8 points |
BHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $748M | +138% |
| Q2 2026 | $593M | +212% |
| Q1 2026 | $121M | +26% |
| Q4 2025 | $403M | -19% |
| Q3 2025 | $314M | -6% |
| Q2 2025 | $190M | -37% |
| Q1 2025 | $96M | -26% |
| Q4 2024 | $495M | +70% |
BHC generated $1.9B in free cash flow over the past year, up 70% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BHC on cash flow, with more consistent year-over-year improvement.
BHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.6M shares |
| 1 year | +1.4% | +5.2M shares |
| 3 years | +4.2% | +15.3M shares |
| 5 years | +4.6% | +16.7M shares |
| Available history | +8.1% | +28.6M shares |
BHC has 381M diluted shares, up 1.4% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.6x | High |
| Q2 2026 | 9.2x | High |
| Q1 2026 | 10.9x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 7.1x | High |
| Q1 2025 | 7.3x | High |
| Q4 2024 | 7.3x | High |
BHC's net debt is about 7.6 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.2 | Overbought |
| Stochastic | 78.2 | Neutral |
BHC's weekly RSI is 71 (overbought) and its Stochastic is 78 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BHC PE vs Healthcare Sector
| Metric | BHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BHC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.86 | 20% above |
| 20 week MA | $6.22 | 33% above |
| 50 week MA | $6.00 | 38% above |
| 100 week MA | $6.22 | 33% above |
| 200 week MA | $7.03 | 17% above |
BHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $20.3 | -32% |
| 2021 | $20.3 | $28.0 | +38% |
| 2022 | $28.0 | $6.33 | -77% |
| 2023 | $6.33 | $8.02 | +27% |
| 2024 | $8.02 | $7.65 | -4.6% |
| 2025 | $7.65 | $7.20 | -5.9% |
| 2026 YTD | $7.20 | $8.25 | +15% |
BHC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.